<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02440230</url>
  </required_header>
  <id_info>
    <org_study_id>RJBC1503</org_study_id>
    <nct_id>NCT02440230</nct_id>
  </id_info>
  <brief_title>Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients</brief_title>
  <acronym>SEAT</acronym>
  <official_title>Safety of Ovarian Function Suppression(OFS)Combined With Different Aromatase Inhibitors(AIs) Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients：A Randomized, Controlled, Prospective, Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare safety of adjuvant OFS combined with anastrozole versus OFS combined with&#xD;
      exemestane in Chinese premenopausal hormonal receptor(HR) positive breast cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of bone or joint pains</measure>
    <time_frame>participants will be followed at 0,3,6,9,12 months from enrollment.</time_frame>
    <description>Bone and joint pains are measured by National Cancer Institute Common Toxicity Criteria for Adverse Effects (NCI CTCAE) classification v4.0 every 3 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>peri-menapausal syndrome</measure>
    <time_frame>KMI score</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>OFS + Anastrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who were anticipated to receive adjuvant OFS+AI endocrine therapy according to MDT discussion results were randomized to this arm,they will receive OFS+Anastrozole.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OFS + Exemestane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who were anticipated to receive adjuvant OFS+AI endocrine therapy according to MDT discussion results were randomized to this arm,they will receive OFS+Exemestane.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OFS + Anastrozole</intervention_name>
    <description>Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or bilateral ovarian irradiation.&#xD;
Patients will take anastrozole 1mg qd.</description>
    <arm_group_label>OFS + Anastrozole</arm_group_label>
    <other_name>OFS + Ana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OFS + Exemestane</intervention_name>
    <description>Patients will take exemestane 25mg qd. Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or bilateral ovarian irradiation.</description>
    <arm_group_label>OFS + Exemestane</arm_group_label>
    <other_name>OFS + EXE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women aged ≥18 years;&#xD;
&#xD;
          2. Histologically confirmed invasive breast cancer by core needle biopsy or&#xD;
             surgery,hormonal receptor positive, defined as estrogen receptor(ER)/progesterone&#xD;
             receptor(PR) positive;&#xD;
&#xD;
          3. Premenopausal defined as&#xD;
&#xD;
               -  who have been menstruating regularly during the 6 months prior to randomization&#xD;
                  and have not used any form of hormonal contraception or any other hormonal&#xD;
                  treatments during the 6 months prior to randomization.&#xD;
&#xD;
               -  premenopausal status confirmed by an estradiol (E2) in the premenopausal range&#xD;
                  after chemotherapy related amenorrhea;&#xD;
&#xD;
          4. Patients must have received standard local therapy: normalized modified radical&#xD;
             mastectomy or breast conserving surgery with negative margin and post-surgical&#xD;
             radiotherapy. Patient should completed adjuvant therapy according to conditions,&#xD;
             including adjuvant radiotherapy, neoadjuvant or adjuvant chemotherapy;&#xD;
&#xD;
          5. Patients who did not receive chemotherapy should be randomized within 24 weeks after&#xD;
             definitive surgery.Patients who received prior adjuvant and/or neoadjuvant&#xD;
             chemotherapy should be randomized after completing chemotherapy and within 8 months of&#xD;
             the final dose of chemotherapy as soon as premenopausal status is confirmed;&#xD;
&#xD;
          6. Leukocyte ≥ 3*109/L; Platelets ≥ 75*109/L; Serum glutamate;&#xD;
&#xD;
          7. oxaloacetate(AST/SGOT) or serum glutamic-pyruvic transaminase(ALT/SGPT) &lt;2.5 times of&#xD;
             upper limit of normal (UNL) range;&#xD;
&#xD;
          8. Serum creatinine/blood urea nitrogen(BUN) ≤ upper limit of normal (UNL) range;&#xD;
&#xD;
          9. Written informed consent according to the local ethics committee requirements.&#xD;
&#xD;
         10. Has Eastern Cooperative Oncology Group(ECOG) Performance Score 0-2;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed hormonal receptor negative.&#xD;
&#xD;
          2. Post-menopausal.&#xD;
&#xD;
          3. Patients with inoperable local advanced breast cancer including inflammatory breast&#xD;
             cancer or supraclavicular node involvement or with enlarged internal mammary nodes&#xD;
             (unless pathologically negative).&#xD;
&#xD;
          4. Definitive surgery was done over 24 weeks before randomization for patients who did&#xD;
             not receive chemotherapy.The final dose of chemotherapy was completed over 8 months&#xD;
             before randomization for patients who received prior adjuvant and/or neoadjuvant&#xD;
             chemotherapy.&#xD;
&#xD;
          5. Pregnant or lactating.&#xD;
&#xD;
          6. Patients with previous or concomitant invasive malignancy are not eligible. The&#xD;
             exceptions are patients with the following (and only the following) malignancies&#xD;
             (previous or concomitant) who are eligible if adequately treated: basal or squamous&#xD;
             cell carcinoma of the skin in situ non-breast carcinoma without invasion contra- or&#xD;
             ipsilateral in situ breast carcinoma non-breast invasive malignancy diagnosed at least&#xD;
             5 years ago and without recurrence:&#xD;
&#xD;
               -  stage I papillary thyroid cancer&#xD;
&#xD;
               -  stage Ia carcinoma of the cervix&#xD;
&#xD;
               -  stage Ia or b endometrioid endometrial cancer&#xD;
&#xD;
               -  borderline or stage I ovarian cancer&#xD;
&#xD;
          7. Patients who received endocrine therapy (including neoadjuvant and adjuvant) for more&#xD;
             than 8 months after their breast cancer diagnosis.&#xD;
&#xD;
          8. Patients who were taking tamoxifen or other selective estrogen receptor modulator&#xD;
             (SERM,e.g. Raloxifene) or hormone replacement therapy (HRT) within one year prior to&#xD;
             their breast cancer diagnosis.&#xD;
&#xD;
          9. Patients who have had a bilateral oophorectomy or ovarian irradiation prior to their&#xD;
             breast cancer diagnosis.&#xD;
&#xD;
         10. With severe hepatic dysfunction, Child-Pugh C.&#xD;
&#xD;
         11. With severe cardiac dysfunction, New York Heart Association (NYHA) grading III or&#xD;
             worse.&#xD;
&#xD;
         12. Known severe hypersensitivity to any drugs in this study.&#xD;
&#xD;
         13. Participants of other experimental drug clinical trials&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kunwei Shen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiahui Huang, MD</last_name>
    <phone>00862164370045</phone>
    <phone_ext>602215</phone_ext>
    <email>hjh3269@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaosong Chen, MD</last_name>
    <phone>00862164370045</phone>
    <phone_ext>602215</phone_ext>
    <email>chenxiaosong0156@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaosong Chen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kunwei Shen, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 2, 2015</study_first_submitted>
  <study_first_submitted_qc>May 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2015</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Kunwei Shen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>adjuvant endocrine therapy</keyword>
  <keyword>safety</keyword>
  <keyword>Exemestane</keyword>
  <keyword>ovarian function suppression</keyword>
  <keyword>anastrozole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Exemestane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

